GenSight Biologics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SIGHT.PA research report →
About the company
GenSight Biologics S. A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system.
- CEO
- Laurence Rodriguez
- IPO
- 2016
- Employees
- 16
- HQ
- Paris, FR
Price Chart
- Market Cap
- $13.14M
- P/E
- -0.99
- P/S
- 13137.80
- P/B
- -0.61
- EV/EBITDA
- -2.10
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1168400.00%
- Net Margin
- -1203600.00%
- ROE
- 42.20%
- ROIC
- 1515.43%
- Revenue
- $1.00K · -99.96%
- Net Income
- $-12,036,000 · 14.03%
- EPS
- $-0.08 · 45.87%
- Op Income
- $-11,705,000
- FCF YoY
- 27.48%
- 52W High
- $0.24
- 52W Low
- $0.08
- 50D MA
- $0.08
- 200D MA
- $0.10
- Beta
- 0.64
- Avg Volume
- 622.82K
Get TickerSpark's AI analysis on SIGHT.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SIGHT.PA coverage
Recent articles, reports, and earnings notes.
No research on SIGHT.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SIGHT.PA report →Similar companies
Peers in the same neighborhood.